Cognition Therapeutics (NASDAQ:CGTX) Upgraded at Brookline Capital Management

Brookline Capital Management upgraded shares of Cognition Therapeutics (NASDAQ:CGTX) to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports. Brookline Capital Management also issued estimates for Cognition Therapeutics’ Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.83) EPS, Q1 2025 earnings at ($0.15) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($0.95) EPS.

CGTX has been the subject of several other research reports. HC Wainwright upped their price target on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. B. Riley upgraded Cognition Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $1.00 to $1.50 in a research note on Thursday, December 19th. Finally, Chardan Capital restated a “buy” rating and set a $11.00 price target on shares of Cognition Therapeutics in a research note on Thursday, December 19th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $8.30.

Cognition Therapeutics Price Performance

Cognition Therapeutics stock opened at $0.76 on Monday. Cognition Therapeutics has a 12 month low of $0.34 and a 12 month high of $2.95. The business has a 50 day simple moving average of $0.61 and a 200-day simple moving average of $0.69. The stock has a market capitalization of $31.61 million, a PE ratio of -0.78 and a beta of 0.95.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CGTX. Virtu Financial LLC purchased a new position in Cognition Therapeutics in the third quarter worth $27,000. SG Americas Securities LLC purchased a new position in shares of Cognition Therapeutics in the fourth quarter valued at $26,000. Sigma Planning Corp increased its position in shares of Cognition Therapeutics by 14.6% in the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after buying an additional 25,050 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV increased its position in shares of Cognition Therapeutics by 33.4% in the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after buying an additional 24,050 shares in the last quarter. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.